Barclays Reaffirms Equal Weight Rating for GSK (LON:GSK)

GSK (LON:GSK)‘s stock had its “equal weight” rating reaffirmed by equities researchers at Barclays in a note issued to investors on Tuesday, Marketbeat.com reports. They currently have a GBX 1,725 ($21.67) target price on the stock. Barclays‘s price objective indicates a potential downside of 2.73% from the stock’s current price.

A number of other research analysts have also recently weighed in on GSK. JPMorgan Chase & Co. lifted their price objective on shares of GSK from GBX 1,530 ($19.22) to GBX 1,660 ($20.85) and gave the company an “underweight” rating in a report on Thursday, May 2nd. Berenberg Bank lifted their price objective on shares of GSK from GBX 1,650 ($20.73) to GBX 1,820 ($22.86) and gave the company a “buy” rating in a report on Wednesday, February 14th. Shore Capital reaffirmed a “buy” rating on shares of GSK in a report on Wednesday, May 1st. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a GBX 1,950 ($24.50) price objective on shares of GSK in a report on Wednesday, April 17th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and three have issued a buy rating to the stock. According to MarketBeat, GSK presently has an average rating of “Hold” and an average price target of GBX 1,675.63 ($21.05).

GSK Stock Performance

GSK opened at GBX 1,773.50 ($22.28) on Tuesday. The firm has a fifty day moving average price of GBX 1,666.29 and a 200 day moving average price of GBX 1,562.88. GSK has a 1 year low of GBX 1,302.60 ($16.36) and a 1 year high of GBX 1,776 ($22.31). The stock has a market cap of £72.54 billion, a P/E ratio of 1,477.92, a P/E/G ratio of 1.12 and a beta of 0.27. The company has a debt-to-equity ratio of 140.82, a current ratio of 0.88 and a quick ratio of 0.73.

Insider Transactions at GSK

In related news, insider Urs Rohner bought 434 shares of the business’s stock in a transaction dated Wednesday, March 20th. The stock was acquired at an average price of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,061.66). In related news, insider Emma Walmsley sold 139,792 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of GBX 1,658 ($20.83), for a total transaction of £2,317,751.36 ($2,911,747.94). Also, insider Urs Rohner acquired 434 shares of the company’s stock in a transaction that occurred on Wednesday, March 20th. The shares were acquired at an average cost of GBX 1,662 ($20.88) per share, with a total value of £7,213.08 ($9,061.66). Corporate insiders own 1.77% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.